ALK and lymphoma: For example, MyD88/TRAF6 and MEK/ERK pathways enhance PD-L1 expression in multiple myeloma (117), while constitutive activation of anaplastic lymphoma kinase (ALK) drives PD-L1 expression in certain lymphomas and lung carcinomas (341, 350).